FGF23 and polycystic ovary syndrome: Beyond levels of bone-related blood markers, BMD was not assessed in this study, which would be a fruitful area for further investigation given the inconsistent clinical evidence regarding the effects of FGF23 on bone mass and fragility fractures in non-PCOS cohorts (the elderly and patients with chronic kidney disease) (72).